- Home
- Publications
- Publication Search
- Publication Details
Title
Novel Treatments in Myasthenia Gravis
Authors
Keywords
-
Journal
Frontiers in Neurology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-07-11
DOI
10.3389/fneur.2020.00538
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis
- (2020) James F. Howard et al. JAMA Neurology
- Immunotherapy Deriving from CAR-T Cell Treatment in Autoimmune Diseases
- (2020) Yuehong Chen et al. Journal of Immunology Research
- Antagonism of the Neonatal Fc Receptor as an Emerging Treatment for Myasthenia Gravis
- (2020) Karissa L. Gable et al. Frontiers in Immunology
- New Approaches to Targeting B Cells for Myasthenia Gravis Therapy
- (2020) Ruksana Huda Frontiers in Immunology
- Complement deposition at the neuromuscular junction in seronegative myasthenia gravis
- (2020) Sarah Hoffmann et al. ACTA NEUROPATHOLOGICA
- ‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab
- (2020) John Vissing et al. JOURNAL OF NEUROLOGY
- Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis
- (2020) Susanna Brauner et al. JAMA Neurology
- Review of the Current Knowledge on the Role of Stem Cell Transplantation in Neurorehabilitation
- (2019) Anna M. Kamelska-Sadowska et al. Biomed Research International
- Bortezomib in antibody-mediated autoimmune diseases (TAVAB): study protocol for a unicentric, non-randomised, non-placebo controlled trial
- (2019) Siegfried Kohler et al. BMJ Open
- Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis
- (2019) Srikanth Muppidi et al. MUSCLE & NERVE
- Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status
- (2019) Grayson Beecher et al. DRUGS
- Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab
- (2019) Kioa Lente Wijnsma et al. CLINICAL PHARMACOKINETICS
- Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis
- (2019) James F. Howard et al. NEUROLOGY
- Efgartigimod
- (2019) Amanda C. Guidon et al. NEUROLOGY
- Myasthenia gravis
- (2019) Nils Erik Gilhus et al. Nature Reviews Disease Primers
- Complement Therapeutics in Autoimmune Disease
- (2019) Joshua M. Thurman et al. Frontiers in Immunology
- Refractory myasthenia gravis successfully treated with ofatumumab
- (2019) Michael J Waters et al. MUSCLE & NERVE
- CAR T-cell Therapy: A New Era in Cancer Immunotherapy
- (2018) Miliotou N. Androulla et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event
- (2018) Joseph R. Berger et al. JOURNAL OF NEUROVIROLOGY
- Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis
- (2018) Karen Hewett et al. NEUROLOGY
- Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action
- (2018) Douglas Sheridan et al. PLoS One
- Targeting B Cells and Plasma Cells in Autoimmune Diseases
- (2018) Katharina Hofmann et al. Frontiers in Immunology
- Adverse Effects of Immunoglobulin Therapy
- (2018) Yi Guo et al. Frontiers in Immunology
- Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans
- (2018) Peter Ulrichts et al. JOURNAL OF CLINICAL INVESTIGATION
- The Use of Human Mesenchymal Stem Cells as Therapeutic Agents for the in vivo Treatment of Immune-Related Diseases: A Systematic Review
- (2018) Alessander Leyendecker Jr. et al. Frontiers in Immunology
- Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study
- (2018) Austin G. Kulasekararaj et al. BLOOD
- M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First-in-Human Study
- (2018) Leona E. Ling et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Autologous Hematopoietic Stem Cell Transplantation for Autoimmune Diseases: From Mechanistic Insights to Biomarkers
- (2018) Kelen Cristina Ribeiro Malmegrim et al. Frontiers in Immunology
- ONX-0914, a selective inhibitor of immunoproteasome, ameliorates experimental autoimmune myasthenia gravis by modulating humoral response
- (2017) Ru-Tao Liu et al. JOURNAL OF NEUROIMMUNOLOGY
- Autologous haematopoietic stem cell transplantation for neurological diseases
- (2017) Joachim Burman et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
- (2017) James F Howard et al. LANCET NEUROLOGY
- Rituximab treatment of myasthenia gravis: A systematic review
- (2017) Rup Tandan et al. MUSCLE & NERVE
- B cells in the pathophysiology of myasthenia gravis
- (2017) John S. Yi et al. MUSCLE & NERVE
- Rituximab as treatment for anti-MuSK myasthenia gravis
- (2017) Michael K. Hehir et al. NEUROLOGY
- Subcutaneous immunoglobulin in myasthenia gravis exacerbation
- (2017) Grayson Beecher et al. NEUROLOGY
- Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab
- (2017) Dagur Ingi Jonsson et al. NEUROMUSCULAR DISORDERS
- The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study
- (2017) Peter Kiessling et al. Science Translational Medicine
- Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience
- (2017) Christiane Schneider-Gold et al. Therapeutic Advances in Neurological Disorders
- B-cell-activating factor is elevated in serum of patients with myasthenia gravis
- (2016) Sa-Yoon Kang et al. MUSCLE & NERVE
- International consensus guidance for management of myasthenia gravis
- (2016) Donald B. Sanders et al. NEUROLOGY
- Treatment for Refractory Myasthenia Gravis—New Lymphs for Old
- (2016) Daniel B. Drachman JAMA Neurology
- Myasthenia Gravis Treated With Autologous Hematopoietic Stem Cell Transplantation
- (2016) Adam Bryant et al. JAMA Neurology
- Toxicity and management in CAR T-cell therapy
- (2016) Challice L Bonifant et al. Molecular Therapy-Oncolytics
- Subcutaneous Immunoglobulin Therapy in the Chronic Management of Myasthenia Gravis: A Retrospective Cohort Study
- (2016) P. R. Bourque et al. PLoS One
- Future perspectives in target-specific immunotherapies of myasthenia gravis
- (2015) Marinos C. Dalakas Therapeutic Advances in Neurological Disorders
- Targeting the Fc receptor in autoimmune disease
- (2014) Xinrui Li et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Intravenous immunoglobulin as treatment for myasthenia gravis: current evidence and outcomes
- (2014) Majed Alabdali et al. Expert Review of Clinical Immunology
- Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma
- (2014) Lenka Kubiczkova et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Targeting complement system to treat myasthenia gravis
- (2014) Ruksana Huda et al. REVIEWS IN THE NEUROSCIENCES
- IgG Subclasses and Allotypes: From Structure to Effector Functions
- (2014) Gestur Vidarsson et al. Frontiers in Immunology
- Subcutaneous IgG in neurologic diseases
- (2013) Melvin Berger Immunotherapy
- Disturbed B cell subpopulations and increased plasma cells in myasthenia gravis patients
- (2013) Siegfried Kohler et al. JOURNAL OF NEUROIMMUNOLOGY
- The thymus in autoimmune Myasthenia Gravis: Paradigm for a tertiary lymphoid organ
- (2013) J.-M. Weiss et al. REVUE NEUROLOGIQUE
- New treatments for myasthenia: a focus on antisense oligonucleotides
- (2013) Corrado Angelini et al. Drug Design Development and Therapy
- Functional defect in regulatory T cells in myasthenia gravis
- (2012) Muthusamy Thiruppathi et al. Annals of the New York Academy of Sciences
- Muscle autoantibodies in myasthenia gravis: beyond diagnosis?
- (2012) Matthew N Meriggioli et al. Expert Review of Clinical Immunology
- CD19 as an attractive target for antibody-based therapy
- (2012) Ohad Hammer mAbs
- Belimumab Is Approved by the FDA: What More Do We Need to Know to Optimize Decision Making?
- (2012) Diane Lewis Horowitz et al. Current Rheumatology Reports
- Molecular Mimicry as a Mechanism of Autoimmune Disease
- (2011) Matthew F. Cusick et al. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
- Complement and cytokine based therapeutic strategies in myasthenia gravis
- (2011) Erdem Tüzün et al. JOURNAL OF AUTOIMMUNITY
- Stem cell transplantation for autoimmune diseases
- (2010) T. Hugle et al. HAEMATOLOGICA
- Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis
- (2010) Revital Aricha et al. JOURNAL OF AUTOIMMUNITY
- The development and function of regulatory T cells
- (2009) Creg J. Workman et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Current Proposed Mechanisms of Action of Intravenous Immunoglobulins in Inflammatory Neuropathies
- (2009) Saiju Jacob et al. Current Neuropharmacology
- Correlation of C3 level with severity of generalized myasthenia gravis
- (2009) Aidong Liu et al. MUSCLE & NERVE
- Classical Complement Pathway in Experimental Autoimmune Myasthenia Gravis Pathogenesis
- (2008) Premkumar Christadoss et al. Annals of the New York Academy of Sciences
- Antisense Treatment for Myasthenia Gravis
- (2008) Jon D. Sussman et al. Annals of the New York Academy of Sciences
- Advances in the understanding of the mechanism of action of IVIg
- (2008) Hans-Peter Hartung JOURNAL OF NEUROLOGY
- Plasma cell development: From B-cell subsets to long-term survival niches
- (2008) Kirsten A. Fairfax et al. SEMINARS IN IMMUNOLOGY
- Steroids and immunosuppressant drugs in myasthenia gravis
- (2008) Sivakumar Sathasivam Nature clinical practice. Neurology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started